Using a glucose measurement system in intensive care for patients with shock
Feasibility of Using the "CGM GUARDIAN 2" Interstitial Fluid Glucose Measurement System in Intensive Care Medicine
This study is testing a new glucose monitoring system to see if it can help make checking blood sugar easier and more comfortable for patients in intensive care who are dealing with septic shock.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 55 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Nice Academic / other |
| Locations | 1 site (Nice) |
| Trial ID | NCT04910841 on ClinicalTrials.gov |
What this trial studies
This study evaluates the feasibility of the 'CGM GUARDIAN 2' system for monitoring glucose levels in patients experiencing hyperglycemia due to septic shock in intensive care units. The traditional method of blood glucose monitoring involves painful capillary sampling every two hours, which can lead to discomfort and sleep disturbances. The 'CGM GUARDIAN 2' system uses a subcutaneously placed electrode to measure glucose levels in interstitial fluid, potentially reducing the need for frequent blood draws. This approach aims to improve patient comfort and glycemic control in critically ill patients.
Who should consider this trial
Good fit: Ideal candidates include patients in septic shock with arterial hypotension requiring noradrenaline and hyperglycemia needing insulin therapy.
Not a fit: Patients who are under guardianship, pregnant, or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance glucose monitoring in intensive care, leading to better management of hyperglycemia and improved patient outcomes.
How similar studies have performed: While the use of continuous glucose monitoring systems has been validated in diabetic patients, this specific application in intensive care settings is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient in septic shock * Arterial hypotension requiring noradrenaline * Hyperglycaemia requiring insulin therapy Exclusion Criteria: * Patients under guardianship, curatorship or deprived of liberty * Pregnant or breastfeeding women
Where this trial is running
Nice
- CHU de Nice — Nice, France (Recruiting)
Study contacts
- Principal investigator: Florent BILGER — Centre Hospitalier Universitaire de Nice
- Study coordinator: Florent BILGER
- Email: bilger.f@chu-nice.fr
- Phone: 492035510
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.